Due to the highly heterogeneous nature of breast cancer, there are significant individual differences between breast cancer patients [9], even patients of breast cancer with the same histological type, TNM stage, and even hormone receptor status, using the same standard treatment regimen recommended by the clinical guidelines, the efficacy and prognosis are often very different [10], so it is extremely important to individualize the treatment of breast cancer patients. This evidence concerns the gene NR4A1 and breast cancer.